Adult Myopia
Adult Myopia Market

Myopia refers to a spectrum of ocular disorders in which the eye’s far point is closer to the retina than infinity. Adult Myopia is becoming a worldwide epidemic and imposes a tremendous public health burden. Consequently, the global initiative for eliminating avoidable blindness has grouped refractive error as one of five leading causes of blindness and visual impairment in the world.

Adult Myopia Symptoms

Various symptoms associated with Adult Myopia are headaches, squinting, eye strain, eye fatigue difficulty seeing while driving, especially at night, and several others.

Adult Myopia Diagnosis

There are certain diagnostic measures that detect Adult Myopia including eye examination, refraction assessment, and eye health exams as well.

Adult Myopia Risk Factors

Certain risk factors related to Adult Myopia are several genetic as well as environmental conditions.

Adult Myopia Epidemiological Segmentation 

The Epidemiological Segmentation of Adult Myopia in 7MM from 2018 to 2030 is segmented into:-

  • Prevalence of Adult Myopia
  • Prevalence of Myopic Choroidal Neovascularization

Adult Myopia Epidemiological Insights Observed in 2018

  • The prevalent cases of Adult Myopia in the United States were observed to be 82,969,055.
  • The prevalent cases of Adult Myopia in Germany were found to be 22,201,829.
  • The prevalent cases of Adult Myopia in Japan were observed to be 34,856,403.

Adult Myopia Market

The market size of Adult Myopia in the 7MM was found to be USD 228.89 million in 2020.

Adult Myopia Emerging Drugs

The emerging drugs of the Adult Myopia market are

  • Lucentis
  • EYLEA, and many others

Adult Myopia Key Players

The key players working in the Adult Myopia market are

  • Genentech
  • Regeneron Pharmaceuticals Inc., and several others